Oragenics reports millions in losses and going concern doubt
Alpha Vantage · Quantisnow · · AI-summarised by FinFlash
Oragenics reported a $7.3 million nine-month net loss and used $6.4 million in operating cash, raising substantial doubt regarding its ability to continue as a going concern. The company warned that research and development programs face delays or abandonment without new financing. For investors, unresolved liquidity risks threaten ongoing clinical operations and potential solvency.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.